| 恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价 |
| |
| 引用本文： | 叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,0(22):147-149. |
| |
| 作者姓名： | 叶向荣 |
| |
| 作者单位： | （九江学院附属医院消化内科，江西 九江 332000） |
| |
| 摘 要： | 目的 观察与评价恩替卡韦治疗慢性乙型肝炎病毒感染患者临床价值。方法 选取2015年10月~2018年7月在我院接受慢性乙型肝炎治疗的患者96例，随机分为对照组与研究组，各48例。对照组选择阿德福韦脂片治疗，研究组选择恩替卡韦治疗。对比两组患者治疗总有效率、不良反应情况，ALT、HBV-DNA水平及HBeAg转阴率指标。结果 研究组的治疗总有效率为95.83%，高于对照组的79.17%，差异有统计学意义（P＜0.05）；研究组患者腹泻、恶心及头晕的发生率均低于对照组，差异有统计学意义（P＜0.05）；治疗后，研究组患者ALT、HBV-DNA水平均高于对照组，差异有统计学意义（P＜0.05）；研究组患者HBeAg效价水平为（2.78±0.56）S/CO，低于对照组的（4.23±1.21）S/CO，差异有统计学意义（P＜0.05）。结论 慢性乙型肝炎病毒感染患者接受恩替卡韦治疗的效果更佳，可有效提升ALT、HBV-DNA水平，降低HBeAg效价水平，不良反应发生率低。
|
| 关 键 词： | 恩替卡韦 慢性乙型肝炎 病毒感染 |
Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection |
| |
| YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,0(22):147-149. |
| |
| Authors: | YE Xiang-rong |
| |
| Affiliation: | (Department of Gastroenterology,Affiliated Hospital of Jiujiang University, Jiujiang 332000, Jiangxi,China) |
| |
| Abstract: | Objective To observe and evaluate the clinical value of entecavir in the treatment of chronic hepatitis B virus infection. Methods 96 patients with chronic hepatitis B treated in our hospital from October 2015 to July 2018 were randomly divided into control group and study group, 48 cases in each group. The control group was treated with adefovir dipivoxil tablet and the study group was treated with entecavir. The total effective rate, adverse reactions, ALT, HBV-DNA levels and HBeAg negative conversion rate were compared between the two groups. Results The total effective rate of the study group was 95.83%, higher than 79.17% of the control group, with significant difference (P<0.05); The incidence of diarrhea, nausea and dizziness in the study group was lower than that in the control group, and the difference was statistically significant (P<0.05). After treatment, the ALT and HBV-DNA levels in the study group were higher than those in the control group,the difference was statistically significant (P<0.05). The HBeAg titer level of the study group was (2.78±0.56) S/CO, which was lower than that of the control group (4.23±1.21) S/CO,the difference was statistically significant (P<0.05). Conclusion Patients with chronic hepatitis B virus infection are more effective in receiving entecavir, which can effectively improve ALT and HBV-DNA levels, lower HBeAg titer, and have a lower incidence of adverse reactions. |
| |
| Keywords: | Entecavir Chronic hepatitis B Viral infection |
|
| 点击此处可从《医学信息》浏览原始摘要信息 |
|
点击此处可从《医学信息》下载全文 |
|
